Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy
- PMID: 18534850
- DOI: 10.1016/j.breast.2008.04.002
Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy
Abstract
Neoadjuvant chemotherapy (NAC) is now a relatively standard treatment for breast carcinoma. However, some tumors are known to develop resistance to chemotherapies. We investigated whether the status of estrogen receptor (ER), progesterone receptor (PR) and Her-2 expressions in breast cancer cases prior to NAC could be changed after NAC. We used immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. No differences were found in ER or Her-2 status, but a significant difference was found in PR status. Changes in Her-2 status were suspected in four specimens after NAC (3+ to 1+ for 3 patients, and 1+ to 3+ for one patient) according to the IHC results. However, in all four of these cases, FISH of the resections showed no change. When IHC indicates a change in Her-2 expression after NAC, FISH is recommended.
Similar articles
-
Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial.
-
[Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].Di Yi Jun Yi Da Xue Xue Bao. 2004 Dec;24(12):1437-9. Di Yi Jun Yi Da Xue Xue Bao. 2004. PMID: 15604081 Chinese.
-
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.J Clin Oncol. 2007 Oct 1;25(28):4423-30. doi: 10.1200/JCO.2007.11.0973. J Clin Oncol. 2007. PMID: 17906205
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
[Neoadjuvant systemic chemotherapy for patients with operable breast cancer].Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):161-5. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17649628 Review. Chinese. No abstract available.
Cited by
-
Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.Sci Rep. 2024 May 23;14(1):11761. doi: 10.1038/s41598-024-62592-0. Sci Rep. 2024. PMID: 38783028 Free PMC article.
-
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer.Cancers (Basel). 2023 Jun 6;15(12):3068. doi: 10.3390/cancers15123068. Cancers (Basel). 2023. PMID: 37370679 Free PMC article.
-
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast Cancer Res Treat. 2023 Jul;200(2):247-256. doi: 10.1007/s10549-023-06978-0. Epub 2023 May 26. Breast Cancer Res Treat. 2023. PMID: 37233961 Free PMC article.
-
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.Cancer Drug Resist. 2022 Oct 20;5(4):971-980. doi: 10.20517/cdr.2022.55. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36627895 Free PMC article.
-
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.Sci China Life Sci. 2022 Nov;65(11):2205-2217. doi: 10.1007/s11427-022-2104-3. Epub 2022 May 13. Sci China Life Sci. 2022. PMID: 35579777
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
